Navigation Links
U of M performs first systemic therapy for fatal childhood disease
Date:11/2/2007

University of Minnesota Childrens Hospital, Fairview physicians have performed the first bone marrow and cord blood transplant to treat recessive dystrophic epidermolysis bullosa (RDEB).

Children with RDEB lack a protein that anchors skin to the body, resulting in fragile skin that sloughs off with little movement or friction. They suffer painful wounds and must be bandaged at all times to protect their skin from further damage and infection. The 18-month-old boy who was transplanted has the most severe form of RDEB, which also causes skin to slough off on the inside of the body, affecting the mouth, esophagus, and gastrointestinal tract. EB is genetic and severe forms are always fatal. Those who live to be young adults get an aggressive form of skin cancer called squamous cell carcinoma.

With the help of an EB mouse model and in collaboration with investigators at Columbia University, University of Minnesota researchers were able to correct the disease in mice using bone marrow. They tested various types of adult stem cells to determine which would give rise to the development of type VII collagen the protein people with RDEB lack. One type of immature cells from bone marrow proved to be the best at producing anchoring fibrils that bind the skin to the body.

This is the first time physicians have approached EB from a systemic perspective, using transplant as a means to rid the body of the defective blood system and replace it with a healthy blood system that produces type VII collagen.

Our goal is to determine the usefulness of stem cells, whether from the umbilical cord blood or adult tissues like bone marrow, in the treatment of human disease, said John E. Wagner, M.D., professor of Pediatrics and director of the Division of Hematology, Oncology, and Blood and Marrow Transplantation and director of clinical research of the Stem Cell Institute at the University of Minnesota. There are hundreds of thousands of children and adults waiting for new breakthroughs in stem cell research, and time is never enough. In two years, the team was able to move this project forward remarkably fastfrom testing in animal models to treating patients. Time will tell whether this risky treatment will work as effectively in humans. But, RDEB is a horribly debilitating, life-threatening disease with no existing curative therapy.

The boy received both umbilical cord blood and bone marrow from a perfectly matched sibling. If the results mimic the animal model, doctors anticipate the healthy blood system will aid in the skins ability to produce type VII collagen necessary to anchor the skin and lining cells of the gastrointestinal tract to the body. Doctors anticipate in early 2008approximately 100 days after transplantthey will be able to judge whether this the treatment helped.

This represents a real change in thinking within the dermatological community. The possibility of this approach compels us to explore more broadly the way some skin diseases are typically treated, said Maria Hordinsky, M.D., head of the Department of Dermatology at the University of Minnesota and member of the care team.


'/>"/>

Contact: Molly Portz
mportz@umn.edu
612-625-2640
University of Minnesota
Source:Eurekalert

Related medicine news :

1. Doctors At The TMCH Performs Their First Open-heart Surgery
2. West Bengal Performs Yagna to Ward off Dengue, Malaria
3. Vanderbilt Performs States First Stem Cell Heart Regeneration Therapy
4. Spanish Doctors Performs Worlds First Hand Transplantation Successfully
5. UK Hospital Performs Heart Surgery Using Robotic Arm
6. First Vaccine Designed for Africa Cleared for Testing in Humans
7. Infant receives first bloodless liver transplant
8. Oracle Corp. to help build worlds first "Digital Hospital"
9. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
10. First human clone is near
11. First Artificial Heart patient has Major setback
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and I wanted ... family recipe, which is meant to relieve gout and pain caused by varicose veins. ... energy boost every time. It relieved what VA doctors called the worst sinusitis case ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , ... and other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger ... vice president of sales. , Litsinger joined Mirixa in 2008 after serving ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to ... that are both engaging and easy to use. Coming off the heels of ... revealed today its plans to roll out new AI-powered self-service enhancements to help ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 9, 2016 Research and Markets has ... Forecast to 2021" report to their offering. ... Market growth ... models in the pharmaceutical and biotechnology industry and technological advancements ... funding. Emerging markets and growing research activities in toxicology and ...
(Date:12/9/2016)... -- RxWiki Inc., a digital health company that powers the ... of pharmacies through its Digital Pharmacist SaaS platform, today ... on Fire" Award in the Health and Life Sciences ... award as one of Austin,s fastest growing companies," said ... "Our platform gives independent retail pharmacies the digital tools ...
(Date:12/9/2016)... SAN DIEGO , Dec. 9, 2016 /PRNewswire/ ... with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ... program targeting ,LpxC, for the treatment of bacterial ... LpxC has been recognized as an attractive antibacterial ... however, a lack of suitable chemical starting points ...
Breaking Medicine Technology: